The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.50
Bid: 1,774.00
Ask: 1,774.50
Change: -3.50 (-0.20%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-FEATURE-As smokers spark up e-cigs to quit, traditional aids suffer

Thu, 29th Jan 2015 06:00

(Repeats with no changes to text)

By Jilian Mincer

NEW YORK, Jan 29 (Reuters) - When Marty Weinstein decided toquit smoking, he took a friend's advice and tried electroniccigarettes rather than government-approved nicotine replacementproducts.

Weinstein, 58, has gone from a pack a day nine months ago tothe equivalent in nicotine of four or five cigarettes. Thee-cigs have a familiar look and feel, and quench his desire tohold on to a cigarette and puff.

"I fully understand I'm still addicted to nicotine," saidWeinstein, a Connecticut taxi driver who had smoked for morethan 20 years. "But I'm now so much healthier."

E-cigarettes, metal tubes that heat liquids typically lacedwith nicotine and deliver vapor when sucked, are transformingthe market for smoking cessation products and slowing the $2.4billion in global sales of long-standing aids such as nicotinepatches and gums. But their impact on health remains unclear,experts say, raising difficult questions for regulators who arestarting to impose limits on e-cigarette use.

E-cigarette makers in the United States are barred fromexplicitly marketing the products as smoking cessation devices,but have found ways to appeal legally to smokers who arethinking of quitting.

"You never say 'quit' because it's not approved by the FDAas a smoking cessation device," said Jose Castro, the chiefexecutive of A1 Vapors in Miami, referring to the U.S. Food andDrug Administration.

A1 Vapors runs an ad on its website urging customers to"kiss tobacco goodbye" and give themselves the "gift of yourlife. literally", adding a disclaimer that e-cigs are not asmoking cessation product.

E-cigarettes, or e-cigs, have only come into widespread usein the past few years, but have already made inroads intotraditional quitting therapies.

About a third of British smokers trying to quit were usinge-cigarettes, according to a University College London survey inJanuary of 1,800 people, including 450 smokers.

E-cigs are used by almost twice as many people asgovernment-approved nicotine gums, lozenges and patches,according to the survey. That was a reversal from 2011, whenonly about 5 percent of people were using e-cigarettes and morethan 30 percent used over-the-counter products.

Similar data is not yet publicly available for the UnitedStates.

Worldwide sales of all nicotine replacement therapies grewjust 1.2 percent last year, to almost $2.4 billion, according todata from commercial researcher Euromonitor. U.S. sales, at $900million, grew 0.2 percent, and are expected by Euromonitor todrop this year by that amount.

Big tobacco companies like Altria, Lorillard and Reynolds American have rushed into the e-cig market.The entire U.S. market for "vapor devices" such as e-cigs grewin 2014 by 40-50 percent to $2.5 billion to $3 billion,Euromonitor said. The global market is worth $5 billion.

RULES ON E-CIGS TIGHTENING

Mark Strobel, a consumer health analyst at Euromonitor, saide-cigarettes have slowed nicotine replacement therapy sales,along with relatively high prices and a shrinking population ofsmokers, especially in the United States.

"For some consumers it has been a direct substitution."

GlaxoSmithKline (GSK) and Johnson & Johnson don't break out the data on their smoking cessation products,which are relatively small parts of their sales, but thecompanies have noted the change.

"It's definitely taken a bit of our market, no question atall - but there's a lot of competition in that space," GSK chiefexecutive Andrew Witty told Reuters in an interview this month.

GSK's nicotine replacement therapies and smoking cessationproducts include the brands Nicorette, NicoDermCQ and themedicine Zyban.

There is little long-term safety data on e-cigarettes,although some healthcare professionals say they may be betterfor consumers than tobacco cigarettes because they have nocarbon monoxide and fewer cancer-causing chemicals.

A growing number of states, cities and countries - includingIsrael and Australia - are considering or have approvedlegislation to ban or limit the devices or the liquids, whichcome in exotic flavors from bacon to bubble gum.

California's top public health official on Wednesday slammede-cigs as addictive, saying they were leading to nicotinepoisoning among children and threatened to unravel the state'sdecades-long effort to reduce tobacco use.

Earlier this week, California introduced a bill that wouldban the devices in public places, and New York Gov. Andrew Cuomoproposed a similar ban earlier this month.

Last year, the World Health Organization recommended thatsmokers should be encouraged to try already approved treatmentsrather than e-cigarettes. The FDA last April proposed rules forelectronic cigarettes that would, among other things, ban salesto those under 18, but not restrict flavored products, onlinesales or advertising.

MAKING SMOKING COOL AGAIN?

Many health experts worry that e-cigarettes will becomeestablished as smoking cessation aids before enough research isdone to determine their health impact. Another concern is thatthey may stop people from quitting tobacco completely and deterpeople from trying potentially more effective methods.

Dr. Albert Rizzo, senior medical advisor for the AmericanLung Association, said that when patients ask about theproducts, he tells them it's good that they are trying to quitbut: "We don't know enough to recommend them."

Some healthcare professionals said that even if they are notopposed to e-cigarettes, they are concerned about theirmarketing, especially to young people.

The Federal Trade Commission declined to comment on specifice-cig ads but said "advertising must be truthful, non-deceptiveand supported by competent and reliable scientific evidence."

E-cigs risk bringing the "cool" back to smoking, reversingthe progress over decades in which smoking has become lesssocially acceptable, said Dr. Robert K. Jackler, a professor atStanford University School of Medicine.

"A lot of us are very concerned about the renormalizationphenomenon," he said. "These glamorize smoking behavior."

Still, some doctors point to the low efficacy of traditionalways to quit smoking.

"They have better results than placebos, but their rates ofsuccess are quite low," said Dr. Michael Siegel, a professor atthe Boston University School of Public Health, who saide-cigarettes are an alternative, especially for people who havetried the conventional therapies and failed. (Additional reporting by Kate C. Kelland and Ben Hirschler inLondon; editing by Peter Henderson and Stuart Grudgings)

More News
Today 15:19

London close: Stocks mixed after disappointing retail sales data

(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted to a larger-than-expected drop in UK retail sales.

Read more
Today 08:55

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April

(Alliance News) - Stock prices in London opened lower on Friday, with sentiment hurt across the globe.

Read more
Today 08:36

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case

(Alliance News) - GSK PLC on Friday welcomed the jury verdict in the Valadez case in Illinois state court, which found in GSK's favour in the first Zantac case to go to trial.

Read more
Today 07:52

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal

(Alliance News) - Stocks are called to open lower on Friday, following New York lower, as hopes of interest rate cuts have come into question.

Read more
Today 07:30

Jury rules in favour of GSK in Zantac trial

(Sharecast News) - A court in Illinois has ruled in favour of GSK in the first Zantac case to go to trial, the UK drugs giant confirmed on Friday.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 08:49

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.

Read more
21 May 2024 07:21

GSK reports promising results from asthma treatment trials

(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.

Read more
20 May 2024 16:11

IN BRIEF: GSK executive buys GBP20,026 worth shares

GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares at 1,788 pence each. Worth total GBP20,026.

Read more
17 May 2024 17:38

London's FTSE nudges lower for week after record run

Haleon falls after GSK offloads remaining stake

*

Read more
17 May 2024 15:52

London close: Stocks recoup some earlier losses

(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.

Read more
17 May 2024 11:52

LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady

(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.

Read more
17 May 2024 09:03

TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion

(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.